Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
25 participants
INTERVENTIONAL
2014-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ICSI group
In this group, sperm selected for injection will be morphologically evaluated under 400x magnification
Intracytoplasmic sperm injection
sperm selection for injection will be performed under 400x magnification
IMSI group
In this group, sperm selected for injection will be morphologically evaluated under 6600x magnification
Intracytoplasmic morphologically selected sperm injection
Sperm selection for injection will be performed at 6600x magnification
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intracytoplasmic morphologically selected sperm injection
Sperm selection for injection will be performed at 6600x magnification
Intracytoplasmic sperm injection
sperm selection for injection will be performed under 400x magnification
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Regular menstrual cycles every 25-35 days.
* Body Mass Index less than 35 as calculated according to the following formula: body weight (kg) / height x height (m2)
* Presence of both ovaries.
* No pelvic and / or clinically significant uterine anomalies.
* Normal cervical cytology.
* Serum follicle stimulating hormone (FSH) within normal limits.
Exclusion Criteria
* Infection by the human immunodeficiency virus (HIV).
* Infection by the by the hepatitis C virus
* Positive test for surface antigens of hepatitis B.
* Endometriosis stages III - IV (classification of the American Society for Reproductive Medicine).
* Hydrosalpinx, unilateral or bilateral.
* Abnormal gynecological bleeding, undiagnosed.
* Allergy or hypersensitivity to human gonadotropin preparations or any other related to the study medication.
-Simultaneous participation in another clinical trial. -
38 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sapientiae Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Edson Borges, PhD
Role: PRINCIPAL_INVESTIGATOR
Sapientiae Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fertility - Centro de Fertilização Assistida
São Paulo, São Paulo, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Sapi IMSI IF
Identifier Type: -
Identifier Source: org_study_id